DYN Insider Trading
Insider Ownership Percentage: 20.77%
Insider Buying (Last 12 Months): $1,057,280.00
Insider Selling (Last 12 Months): $12,878,411.80
Dyne Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Dyne Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Dyne Therapeutics Share Price & Price History
Current Price: $9.42
Price Change: ▼ Price Decrease of -0.49 (-4.94%)
As of 04/3/2025 05:00 PM ET
Dyne Therapeutics Insider Trading History
Dyne Therapeutics Institutional Trading History
Data available starting January 2016
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More on Dyne Therapeutics
Volume
1,702,902 shs
Average Volume
1,420,250 shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.11
Who are the company insiders with the largest holdings of Dyne Therapeutics?
Dyne Therapeutics' top insider shareholders include:
- Jason P Rhodes (Director)
- Venture Fund Xi LP Atlas (Major Shareholder)
- Dirk Kersten (Director)
- Joshua T Brumm (CEO)
- Joshua T Brumm (Insider)
- Oxana Beskrovnaya (Insider)
- Susanna Gatti High (COO)
- Wildon Farwell (Insider)
- Jonathan Mcneill (Insider)
- Richard William Scalzo (Insider)
- Richard William Scalzo (SVP)
- Johanna Friedl-Naderer (Insider)
- John Cox (CEO)
- Carlo Incerti (Director)
Learn More about top insider investors at Dyne Therapeutics.